Investor's Business Daily
IPO Stock Taps Massive Medicare Market, Soars Into Buy Range
📊
AI Sentiment
Positive
6/10
- Home
- BLLN
BLLN
BillionToOne Inc.
as of 12-03-2025 3:56pm EST
$100.35
$14.57
-12.68%
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.
Upcoming Earnings Alert:
Get ready for potential market movements as BillionToOne Inc. (BLLN) prepares to release earnings report on 09 Dec 2025.
Chart Type:
Time Range:
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | N/A |
| Market Cap: | 5.0B | IPO Year: | 2025 |
| Target Price: | $138.67 | AVG Volume (30 days): | 270.6K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $88.00 - $138.70 | Next Earning Date: | 12-09-2025 |
| Revenue: | $209,032,000 | Revenue Growth: | 112.72% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BillionToOne Inc. News
BLLN Breaking Stock News: Dive into BLLN Ticker-Specific Updates for Smart Investing
Compare BLLN vs Leading Stocks
See how BLLN stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BLLN BillionToOne Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.